Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Consultant-Needed-Insert
    X

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Prilenia therapeutics

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              ISRAEL Israel

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              AFSSI Connexions 2020

              Participation Not Confirmed

              Update your events

              Prilenia Therapeutics Raises $62.5M to Fund Late Stage Trials In HD and ALS

              Contact the Supplier

              Lead Product(s): Pridopidine

              Therapeutic Area: Genetic Disease Product Name: Undisclosed

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Morningside Venture

              Deal Size: $62.5 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing June 03, 2020

              Details:

              The proceeds will fund two late-stage trials, which could lead to the registration of pridopidine for the treatment of HD and ALS. Pridopidine is a highly selective sigma-1 receptor (S1R) agonist.

              Protalix BioTherapeutics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              ISRAEL Israel

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              AFSSI Connexions 2020

              Participation Not Confirmed

              Update your events

              Protalix BioTherapeutics and Chiesi Global Rare Diseases Submits BLA to U.S. Food and Drug Administration for Pegunigalsidase Alfa

              Contact the Supplier

              Lead Product(s): Pegunigalsidase alfa

              Therapeutic Area: Genetic Disease Product Name: Undisclosed

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 28, 2020

              Details:

              The BLA has been filed for pegunigalsidase alfa for the proposed treatment of adult patients with Fabry disease via the FDA's Accelerated Approval pathway. Pegunigalsidase alfa a long-acting recombinant, PEGylated, cross-linked α-galactosidase-A product.

              Protalix BioTherapeutics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              ISRAEL Israel

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              AFSSI Connexions 2020

              Participation Not Confirmed

              Update your events

              Protalix BioTherapeutics Announces Topline Results from the BRIDGE Phase III Open-Label Trial of Pegunigalsidase Alfa in Fabry Disease

              Contact the Supplier

              Lead Product(s): Pegunigalsidase alfa

              Therapeutic Area: Genetic Disease Product Name: Undisclosed

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 11, 2020

              Details:

              The BRIDGE study was a Phase III study evaluating the safety and efficacy of pegunigalsidase alfa, 1 mg/kg infused every two weeks, in up to 22 Fabry patients previously treated with agalsidase alfa.

              Protalix BioTherapeutics

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              ISRAEL Israel

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              AFSSI Connexions 2020

              Participation Not Confirmed

              Update your events

              Protalix BioTherapeutics Announces $43.7 Million in Financing

              Contact the Supplier

              Lead Product(s): Pegunigalsidase alfa

              Therapeutic Area: Genetic Disease Product Name: Undisclosed

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Psagot Investment House

              Deal Size: $43.7 million Upfront Cash: Undisclosed

              Deal Type: Financing March 12, 2020

              Details:

              Financing will advance the Company's clinical programs and commercialization of PRX-102 for the treatment of Fabry disease, as well as to further develop its early stage pipeline of therapeutics.

              Protalix BioTherapeutics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              ISRAEL Israel

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              AFSSI Connexions 2020

              Participation Not Confirmed

              Update your events

              Protalix Presents Key Clinical Data of Pegunigalsidase Alfa

              Contact the Supplier

              Lead Product(s): Pegunigalsidase alfa

              Therapeutic Area: Genetic Disease Product Name: Undisclosed

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 10, 2020

              Details:

              Phase I/II dose-ranging studies show high correlation between two Fabry disease biomarkers, supporting potential effectiveness of pegunigalsidase alfa in treating Fabry disease.

              PharmaCompass__DigitalAd